Boehringer Ingelheim And Inflammasome Therapeutics Inc. (Inflammasome) Today Announced They Have Entered Into A Co-Development And License Agreement To Develop Up To Three Therapies For Patients With Retinal Diseases. By Combining Inflammasome’S Unique Intravitreal (Ivt) Drug Delivery Technologies With Boehringer Ingelheim’S Compounds From Its Retinal Disease Pipeline Portfolio, Boehringer Ingelheim Aims To Develop Novel Therapies For Retinal Diseases.In 2019 There Were An Estimated 82 Million Patients In The Seven Key Countries (U.S., Japan, Germany, U.K., Spain, Italy, France) Affected By One Of The Three Major Forms Of Retinal Disease: Age Related Macular Degeneration (Amd), Diabetic Retinopathy (Dr), And Diabetic Macular Edema (Dme). Globally, The Prevalence Rates Of These And Other Retinal Diseases Are Expected To Increase Over The Next 10 Years Primarily Due To Aging Populations And The Global Diabetes Epidemic. Despite Therapeutic Advances In Some Disease Areas During The Past Years, The Real World Results Are Poor, And There Are No Or Only Limited Treatment Options In Many Areas, Resulting In An Overall High Unmet Need. The Collaboration Between Boehringer Ingelheim And Inflammasome Aims To Address This Challenge By Using Inflammasome’S Technology To Deliver Therapeutics In A Biodegradable Gel Formulation Into The Eye.
